Some California stem cell clinics use unproven therapies. A new court
ruling cracks down
Send a link to a friend
[October 05, 2024]
By ANA B. IBARRA/CalMatters
Stem cell clinics have popped up throughout California, promising cures
and relief for arthritis, Alzheimer’s and other conditions through
cutting-edge technologies. Some, however, are offering services that
have not been approved by federal health regulators.
The U.S. Food and Drug Administration last week gained a significant
court win against stem cell clinics that promote and administer unproven
therapies.
A three-judge panel on the 9th U.S. Circuit Court of Appeals ruled that
the FDA can regulate two affiliated Southern California stem cell
clinics and their treatments after a lower court had exempted them from
regulation.
The decision, experts say, reasserts the FDA’s authority over
regenerative medicine at a time when clinics advertising these types of
stem cell products are booming. Unproven therapies have led to
infections, disabilities and even death, according to adverse reaction
reports.
The case dates to 2018, when the FDA sued the California Stem Cell
Treatment Center Inc., which has clinics in Rancho Mirage and Beverly
Hills, for “improperly manufacturing and labeling” an unapproved
product.
The FDA sought to stop the clinics from administering a so-called
therapy that takes fat tissue from a patient to create a mixture of
cells known as stromal vascular fraction. This is then injected back
into the patient to treat a problem area, such as the knee for
osteoarthritis.
“In recent years, clinics offering similar stem cell mixtures have
proliferated despite concerns over whether such treatments are safe and
effective,” one of the 9th Circuit judges wrote.
As stated in the appeals court ruling, the clinics advertised technology
that could alleviate dozens of medical conditions, including arthritis,
multiple sclerosis, Parkinson’s and heart problems, among others.
Because these treatments are not covered by insurance, people seeking
these products pay tens of thousands of dollars out of pocket. A
12-treatment option could cost $41,500, the decision documents show.
The stem cell clinics countered that the treatment should be exempt from
FDA oversight because it was more like a surgery than a new drug. In
2022, a federal judge ruled in favor of the clinics and the FDA
appealed.
Experts say this most recent ruling strengthens the FDA’s authority over
stem cell therapies and will help keep patients safe. It also matches
the outcome of an earlier case where the FDA sued a Florida stem cell
clinic for administering a similar product and won, barring the clinic
from selling such treatment.
“Now there is a coherent federal legal picture that this product can be
regulated by the FDA as a drug. As a result, these cells cannot legally
be used on patients by stem cell clinics without working with the agency
first,” Paul Knoepfler, a professor of cell biology and human anatomy at
the University of California, Davis, said via email. “Hundreds of
clinics had been marketing them around the U.S. without FDA permission.”
An FDA spokesperson declined to comment on the ruling, saying the agency
does not comment on ongoing litigation. Attorneys for the clinics did
not return requests for comment.
[to top of second column]
|
The landscape of stem cell
therapies
The FDA has issued multiple public warnings about stem cell
treatments because of their popularity. In its notices, the FDA
writes that the only treatments approved for consumers consist of
blood-forming stem cells, which are used to fight certain cancers or
blood disorders. The list of therapies ready for commercial use is
short, experts say. Other types of stem cell treatments have been
approved for clinical trials only.
Every drug and therapy approved in the U.S. has to first go through
a rigorous and lengthy process that includes a clinical trial to
prove it is both safe and effective.
“Please know that if you are being charged for these products or
offered these products outside of a clinical trial, you are likely
being deceived and offered a product illegally,” the FDA wrote in a
warning to consumers in 2021.
Unapproved stem cell products are not only illegal but also
dangerous. In a high profile case, three elderly women went blind
after receiving an unproven fat tissue-based stem cell treatment for
macular degeneration at a Florida clinic, the same one that was
later sued by the FDA. According to news reports from when the case
was first made public, the women sought treatments because they had
difficulty reading fine print. After the procedures, the women
suffered detached retinas, vision loss and bleeding inside the eye.
‘You see them on billboards’
The California Institute for Regenerative Medicine, the
multi-billion dollar agency voters authorized in 2004 to fund stem
cell research, also warns on its website against companies that
promote “bogus therapies.”
“The general public knows that stem cells are a very important field
that continues to develop, and they believe, as we certainly do,
that they’re going to be the source of therapies and cures. The
problem is these companies make it sound like we’re there already,
and that’s just not the case,” said Jonathan Thomas, president of
the agency.
Thomas said last week’s ruling is important because not only does it
send a message to clinics that they can’t provide treatments without
regulation, but it also gives a nod to researchers who are doing
legitimate stem cell work and following the rules.
It’s also a warning for consumers, he said.
It is difficult to track these clinics advertising unapproved cures,
so it is unclear how many are operating today. “We just know that
they are proliferating because you see signs for them…you see them
on billboards, you see ads, you see all sorts of things,” Thomas
told CalMatters.
People who are considering a stem cell treatment should ask if the
therapy has been approved by the FDA. Thomas said the public should
be wary if a stem cell clinic says they are exempt from federal
regulation. “Anytime you hear anything like that, I would say that’s
a huge red flag,” he said.
___
This story was originally published by CalMatters and distributed
through a partnership with The Associated Press.
All contents © copyright 2024 Associated Press. All rights reserved |